A. Toms

Proceedings of the National Academy of Sciences of the United States of America · 2008

A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Whom A. Toms trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Randy J. Read

Papers from A. Toms's perspective

Ordered by how strongly the researchers A. Toms trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Refinement of macromolecular structures by the maximum-likelihood method.
  2. Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* (Journal of Biological Chemistry)
  3. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. (Cell)
  4. Pushing the boundaries of molecular replacement with maximum likelihood.
  5. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. (Cancer Cell)
  6. Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors (Clinical Cancer Research)
  7. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. (Proceedings of the National Academy of Sciences of the United States of America)
  8. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. (Cancer Cell)
  9. Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib (Clinical Cancer Research)
  10. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes.

Their papers